Es gab 50 kürzliche Insider-Transaktionen für Ventyx Biosciences, Inc. (VTYX), darunter 24 Käufe und 24 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $7M und die gesamten Insider-Verkäufe auf $2.56M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Subramaniam Somu, Hulme Allison, Gujrathi Sheila. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — VTYX
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2025-06-05 |
Subramaniam Somu |
Director |
RSU-Zuteilung |
40,000 |
$2.25 |
$90K |
40,000 |
| 2025-06-05 |
Hulme Allison |
Director |
RSU-Zuteilung |
40,000 |
$2.25 |
$90K |
40,000 |
| 2025-06-05 |
Gujrathi Sheila |
Director |
RSU-Zuteilung |
40,000 |
$2.25 |
$90K |
40,000 |
| 2025-06-05 |
White William Richard |
Director |
RSU-Zuteilung |
40,000 |
$2.25 |
$90K |
40,000 |
| 2025-06-05 |
Cadoret-manier Onaiza |
Director |
RSU-Zuteilung |
40,000 |
$2.25 |
$90K |
40,000 |
| 2025-05-15 |
Forman Mark S |
Chief Medical Officer |
RSU-Zuteilung |
3,000 |
$1.03 |
$3.09K |
3,000 |
| 2025-05-15 |
Gonzales Roy |
Senior VP, Finance |
RSU-Zuteilung |
1,750 |
$1.03 |
$1.8K |
3,546 |
| 2025-04-02 |
Nuss John |
Chief Scientific Officer |
Informierter Verkauf |
1,887 |
$1.07 |
$2.02K |
467,226 |
| 2025-03-28 |
Subramaniam Somu |
Director |
Sonstige (Verkauf) |
1,335,450 |
- |
- |
4,032,213 |
| 2025-03-28 |
Nuss John |
Chief Scientific Officer |
Optionsausübung (Verkauf) |
4,531 |
- |
- |
9,063 |
| 2025-03-28 |
Mohan Raju |
CEO and President |
Optionsausübung (Verkauf) |
11,844 |
- |
- |
23,688 |
| 2025-03-10 |
Subramaniam Somu |
Director |
Sonstige (Verkauf) |
1,735,306 |
- |
- |
5,367,663 |
| 2025-01-02 |
Moore Matthew Richard |
Chief Operating Officer |
RSU-Zuteilung |
145,000 |
$2.14 |
$310.3K |
145,000 |
| 2025-01-02 |
Nuss John |
Chief Scientific Officer |
RSU-Zuteilung |
170,104 |
$2.14 |
$364.02K |
170,104 |
| 2025-01-02 |
Mohan Raju |
CEO and President |
RSU-Zuteilung |
700,000 |
$2.14 |
$1.5M |
700,000 |
| 2025-01-02 |
Forman Mark S |
Chief Medical Officer |
RSU-Zuteilung |
85,000 |
$2.14 |
$181.9K |
85,000 |
| 2025-01-02 |
Gonzales Roy |
Senior VP, Finance |
RSU-Zuteilung |
17,500 |
$2.14 |
$37.45K |
17,500 |
| 2024-12-27 |
Nuss John |
Chief Scientific Officer |
Informierter Verkauf |
21,119 |
$2.36 |
$49.84K |
464,582 |
| 2024-12-23 |
Gujrathi Sheila |
Director |
Informierter Kauf |
130,000 |
$2.31 |
$300.57K |
130,000 |
| 2024-12-19 |
Nuss John |
Chief Scientific Officer |
Informierter Verkauf |
13,161 |
$2.26 |
$29.68K |
485,701 |
| 2024-12-17 |
Nuss John |
Chief Scientific Officer |
Optionsausübung (Verkauf) |
34,930 |
- |
- |
34,930 |
| 2024-12-17 |
Mohan Raju |
CEO and President |
Optionsausübung (Verkauf) |
116,668 |
- |
- |
116,668 |
| 2024-12-10 |
Nuss John |
Chief Scientific Officer |
Optionsausübung (Verkauf) |
193,557 |
$0.20 |
$38.71K |
- |
| 2024-11-25 |
Mohan Raju |
CEO and President |
Informierter Kauf |
261,752 |
$2.01 |
$524.94K |
2,175,028 |
| 2024-11-22 |
Mohan Raju |
CEO and President |
Informierter Kauf |
238,248 |
$1.83 |
$434.95K |
1,913,276 |
| 2024-08-30 |
Gonzales Roy |
Senior VP, Finance |
Veräußerung |
70,000 |
$33.84 |
$2.37M |
- |
| 2024-08-12 |
Forman Mark S |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2024-08-12 |
Forman Mark S |
Chief Medical Officer |
RSU-Zuteilung |
350,000 |
$1.95 |
$682.5K |
350,000 |
| 2024-06-24 |
Subramaniam Somu |
10 Percent Owner |
Sonstige (Verkauf) |
641,327 |
- |
- |
7,102,969 |
| 2024-06-24 |
Nsv Partners Iii Lp |
10 Percent Owner |
Sonstige (Verkauf) |
641,327 |
- |
- |
7,102,969 |
| 2024-06-10 |
Mohan Raju |
CEO and President |
Optionsausübung (Verkauf) |
96,778 |
$0.20 |
$19.36K |
- |
| 2024-06-06 |
Subramaniam Somu |
10 Percent Owner |
RSU-Zuteilung |
33,000 |
$3.29 |
$108.41K |
33,000 |
| 2024-06-06 |
Hulme Allison |
Director |
RSU-Zuteilung |
33,000 |
$3.29 |
$108.41K |
33,000 |
| 2024-06-06 |
Gujrathi Sheila |
Director |
RSU-Zuteilung |
33,000 |
$3.29 |
$108.41K |
33,000 |
| 2024-06-06 |
White William Richard |
Director |
RSU-Zuteilung |
33,000 |
$3.29 |
$108.41K |
33,000 |
| 2024-06-06 |
Cadoret-manier Onaiza |
Director |
RSU-Zuteilung |
33,000 |
$3.29 |
$108.41K |
33,000 |
| 2024-05-16 |
Moore Matthew Richard |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2024-05-16 |
Moore Matthew Richard |
Chief Operating Officer |
RSU-Zuteilung |
320,000 |
$4.98 |
$1.59M |
320,000 |
| 2024-04-12 |
Subramaniam Somu |
10 Percent Owner |
Sonstige (Verkauf) |
695,339 |
- |
- |
7,744,296 |
| 2024-04-12 |
Nsv Partners Iii Lp |
10 Percent Owner |
Sonstige (Verkauf) |
695,339 |
- |
- |
7,744,296 |
| 2024-04-02 |
Krueger Christopher W |
Chief Business Officer |
Informierter Verkauf |
1,651 |
$5.40 |
$8.92K |
284,999 |
| 2024-04-02 |
Nuss John |
Chief Scientific Officer |
Informierter Verkauf |
1,651 |
$5.40 |
$8.92K |
264,998 |
| 2024-04-02 |
Auster Martin |
Chief Financial Officer |
Informierter Verkauf |
1,405 |
$5.40 |
$7.59K |
24,303 |
| 2024-04-02 |
Mohan Raju |
CEO and President |
Informierter Verkauf |
4,312 |
$5.40 |
$23.3K |
1,578,250 |
| 2024-03-28 |
Krueger Christopher W |
Chief Business Officer |
Optionsausübung (Verkauf) |
4,531 |
- |
- |
13,594 |
| 2024-03-28 |
Nuss John |
Chief Scientific Officer |
Optionsausübung (Verkauf) |
4,531 |
- |
- |
13,594 |
| 2024-03-28 |
Auster Martin |
Chief Financial Officer |
Optionsausübung (Verkauf) |
4,531 |
- |
- |
13,594 |
| 2024-03-28 |
Mohan Raju |
CEO and President |
Optionsausübung (Verkauf) |
11,843 |
- |
- |
35,532 |
| 2024-01-21 |
Subramaniam Somu |
10 Percent Owner |
RSU-Zuteilung |
20,000 |
$1.97 |
$39.4K |
20,000 |
| 2024-01-21 |
Hulme Allison |
Director |
RSU-Zuteilung |
20,000 |
$1.97 |
$39.4K |
20,000 |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
